



Steven Bellone  
Suffolk County Executive

DRAFT MINUTES  
IDA REGULAR MEETING  
MAY 28, 2020

Present: Natalie Wright, Chair  
Kevin Harvey, Vice Chair  
Anthony Giordano, Secretary  
Gregory Casamento, Member  
Josh Slaughter, Member

Excused Absence: Sondra Cochran, Treasurer

Also Present: Anthony Catapano, Executive Director  
Kelly Morris, Deputy Executive Director  
Daryl Leonette, Executive Assistant  
Regina Halliday, Bookkeeper  
William Wexler, Esq., Agency Counsel  
William Weir, Esq., Nixon Peabody LLC, Transaction Counsel  
Andrew Komaromi, Esq., Harris Beach PLLC, Transaction Counsel  
Shali Natesan, Esq., Barclay Damon LLP, Transaction Counsel,  
William Dudine, Esq., Katten Muchin Rosenman LLP, Transaction Counsel  
Greg Gordon, ZE Creative Communications  
Guy Germano, Esq., Germano & Cahill, P.C., Company Counsel  
Mohit Mundra, Head of Finance, InvaGen Pharmaceuticals, Inc.

The Regular Meeting of the Suffolk County Industrial Development Agency was held remotely via Zoom. Members of the public were able to listen and view the Meeting through the Agency's website via its YouTube Channel. The Meeting was called to order at 1:30 p.m. by Natalie Wright, Chair of the IDA.

Ms. Wright stated this is the May 28, 2020 Regular Meeting of the Suffolk County Industrial Development Agency and for the record we have a quorum present on Zoom. The notice of the meeting followed the Open Meetings Law and the Meeting is being held pursuant to Executive Order 202.1 (2020) and further extended as set forth by the Governor of NYS.

Ms. Wright asked Mr. Catapano to proceed with the Meeting. Mr. Catapano proceeded with the roll call of Board Members, also present were staff members, agency counsel, and transaction counsels. Ms. Wright stated for the Public Comment portion of the Agenda the public may submit comments via email to [info@suffolkida.org](mailto:info@suffolkida.org) or they may be mailed to the Suffolk County Industrial Development Agency.

**NEW BUSINESS****InvaGen Pharmaceuticals, Inc.:** Request for an inducement resolution for a lease transaction.

Mr. Catapano presented Exhibit A. InvaGen Pharmaceuticals, Inc. is a wholesale manufacturer of generic pharmaceutical prescription drugs. InvaGen has three locations in Suffolk County (7 Oser Avenue, Hauppauge; 550 S. Research Place, Central Islip and 600 Old Willets Path, Hauppauge). The Company is an Indian based and owned company and they were purchased by a public company, CIPLA in 2016. InvaGen Pharmaceuticals, Inc. was founded in 2003 and in 2004 the Agency assisted InvaGen at their 7 Oser Avenue, Hauppauge facility. At that time, the Company said they would create 50 jobs and they now have over 580 jobs at their three locations. InvaGen Pharmaceuticals, Inc. has also received assistance from the Town of Islip IDA for their Central Islip location. They currently lease 600 Old Willets Path, Hauppauge and the lease is expiring and they would like to commit to 10 years on their lease. Mr. Catapano indicated the building is 69,654 square feet and the Company proposes to renovate their workspace, modernize its industrial manufacturing operations and purchase equipment. They have a growth plan for the next 10 years which the Company's representative will explain in their presentation.

Mr. Catapano introduced Mohit Mundra, Head of Finance, InvaGen Pharmaceuticals, Inc. and Guy Germano, Esq., Germano & Cahill, PC, Company Counsel to Board Members. Mr. Germano stated as Mr. Catapano mentioned they are a wholly owned subsidiary of CIPLA LTD. which transfers back to an Indian Company. InvaGen was purchased by CIPLA in February, 2016 they are a manufacturer and distributor of pharmaceutical drugs in the US market. The Company employs 586 people in three locations. This application is specific for the lease renewal of 600 Old Willets Path, Hauppauge. The Company will make an investment of \$2.6 million in the building of manufacturing equipment and will commit to the current level of employment. Mr. Germano said the assistance from the Suffolk County IDA and with the Company's investment, it is designed to assure the Company remains competitive. The average salary is \$61,000 with benefits and a 401K plan. Mr. Germano stated InvaGen imports all of its raw materials from Taiwan and India nothing is sourced from China. Their products are supplied through subsidiary companies throughout the United States. Mr. Mundra stated he has been employed by InvaGen for approximately four years. InvaGen has three manufacturing facilities (7 Oser Avenue, Hauppauge; 550 Research Place, Central Islip) and including the facility presented today at 600 Old Willets, Hauppauge. Mr. Mundra provided an overview of the Company with a slide presentation to Board Members.

Mr. Harvey asked is there an estimate of how many temporary jobs will be created. Mr. Mundra responded plans for expansion have been on hold due to the current COVID 19 situation. We will continue with the same payroll when things improve but we have plans for the future. Mr. Harvey said currently you don't project any new jobs however, the modernization of the plant will not affect any jobs is that correct and Mr. Mundra replied yes. Mr. Slaughter said if you do not receive assistance will you have to reduce your payroll and Mr. Mundra replied if we don't receive assistance it will affect our business. Ms. Wright said these improvements will help you remain competitive in the market and Mr. Mundra agreed. Mr. Slaughter said the commitment is to maintain the workforce and if there is a reduction in the workforce we could recapture benefits and Mr. Catapano said correct. Mr. Catapano said we met with the Company earlier this year. The Company believes they are looking at it long term and there will be net increases in jobs above the current 202 employees. The Company said they feel uncomfortable committing additional jobs due to the current pandemic. Mr. Catapano said in their application it states that if the Company cannot fulfill their customer needs for products they sub contract manufacturing out to other pharmaceutical companies in Suffolk County to fill the need. Mr. Catapano said the pharmaceutical industry is a major employer in the

County and important to the Long Island community. Mr. Harvey said this is a leap of faith on our part as we give these rebates on tax structure and we hope it comes to fruition because we answer to the taxpayer. Mr. Catapano asked Mr. Mundra if he is aware of this and Mr. Mundra replied yes. Mr. Mundra stated due to the current virus pandemic situation we have not projected additional employees for the project. Once the situation improves we have expansion plans for the Company. Mr. Catapano stated they are maintaining their level of jobs and they are investing \$2.6 million dollars. Mr. Catapano stated Mr. Harvey had asked previously about construction jobs and it is estimated five construction jobs will be created. Mr. Giordano asked how long before we expect them to increase their job level and Mr. Catapano said their proposal does not include any new jobs in the first two years but the Company said it will add new jobs in the long term with respect to the project. The Company today has almost 600 jobs in Suffolk County and with their project in 2004, they estimated 50 jobs and have exceeded their estimates and have a good employment track record.

Mr. Giordano asked if not for the current pandemic would the Company submit an application with no additional jobs. Mr. Catapano responded when we met with the Company earlier this year they were discussing increases in net jobs. Essential businesses have also been impacted by the pandemic. Mr. Slaughter said I want to establish the need, without tax structure approved would you be able to move forward. Mr. Mundra replied some of them are essential to continue with operations.

After further discussion and;

Upon a motion by Mr. Harvey, seconded by Mr. Casamento, it was:

RESOLVED, to approve an inducement resolution for a lease transaction in the approximate amount of \$2,651,000 for InvaGen Pharmaceuticals, Inc. facility.

Unanimously carried 5/0.

A roll call was taken and it was unanimously carried 5/0.

### Minutes

The Minutes of the IDA Special Meeting April 14, 2020 and April 23, 2020 IDA Meeting were accepted by Board Members.

Ms. Wright stated recent proposed NYS Legislation will allow IDA's to make loans and grants to small businesses. We will take a look at it for the Suffolk County IDA and/or possibly collaborate with other IDA's.

There being no further business Ms. Wright adjourned the Meeting and thanked the Members for their participation.

The Meeting adjourned at 2:20 p.m.

The next meeting of the Suffolk County Industrial Development Agency is tentatively scheduled for June 25, 2020.

**SCIDA PROJECT ABSTRACT**

MEETING DATE: May 28, 2020

CONTACT: Mohit Mundra, Head of Finance  
PHONE #: 516-456-4573

APPLICANT NAME: InvaGen Pharmaceuticals, Inc.  
AND ADDRESS 7 Oser Avenue  
Hauppauge, NY 11788

PRINCIPALS: Cipla (EU) Ltd. (100%)

PRODUCT/SERVICES: Wholesale manufacturer of generic pharmaceutical prescription drugs.

PRESENT FACILITIES: Own \_\_\_\_\_ Lease X Acreage 4.537 Sq. Ft. 69,654  
Invagen also operates and manufactures in two other facilities in Suffolk County (7 Oser Ave, Hauppauge & 550 South Research Place, Central Islip).

LOCATION/TAX MAP #: 600 Old Willets Path, Hauppauge, NY 11788  
Tax Map # 800-185-1-50.2

PROJECT DESCRIPTION: Lease, renovate and equip an existing 69,654 sq. ft. building located at 600 Old Willets Path, Hauppauge, NY 11788. InvaGen intends to renovate their workspace and modernize its industrial manufacturing and purchase equipment in order to maintain its competitive position in the pharmaceutical industry and maintain their current level of employment.

PROJECT COSTS: AUTHORIZATION SOUGHT: \$2,651,000 Lease Transaction

RENOVATIONS TO AN EXISTING BUILDING 1,020,000  
MANUFACTURING EQUIPMENT 1,631,000

TOTAL PROJECT COSTS \$2,651,000

EMPLOYMENT:

	<u># OF EMPLOYEES</u>	<u>ANNUAL PAYROLL</u>	<u>AVERAGE SALARY</u>
PRESENT (All Facilities-Suffolk Crnty.)	586	\$32,250,205	\$58,848
PRESENT (600 Old Willets Path)	202	12,320,550	60,993
PROPOSED 1ST. YEAR	202	12,320,550	60,993
2ND. YEAR	202	12,320,550	60,993

COMMENTS: